RxDoctor Payments Data

John Reyes, MD

Geriatric Medicine · Oyster Bay, NYNPI 1295888709

Payments from drug & device makers

$364in general payments, 2019–2025

Across 12 payments — averaging $30.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$160
  • Apollo Endosurgery US Inc$149
  • Xeris Pharmaceuticals, Inc.$24
  • AstraZeneca$16
  • Abbott$15

What the payments were for

  • Food & beverage$364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364 in reported general payments places this provider in the 70th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$569,779
Medicare patients
999
Services billed
5,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban508$271,546
MounjaroTirzepatide213$244,444
JardianceEmpagliflozin146$157,250
OzempicSemaglutide58$104,878
FarxigaDapagliflozin Propanediol165$96,931
OxycontinOxycodone Hcl41$67,581
SynjardyEmpagliflozin/Metformin Hcl105$66,332
JanuviaSitagliptin Phosphate83$57,247
RybelsusSemaglutide43$55,954
SantylCollagenase Clostridium Hist.71$40,317
GemtesaVibegron99$36,735
XareltoRivaroxaban38$32,609
EntrestoSacubitril/Valsartan49$26,559
IsentressRaltegravir Potassium24$23,707
Tresiba Flextouch U-100Insulin Degludec23$18,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$16$96,931165 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$160$31,36054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Oyster Bay

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →